Provenge, Jevtana Covered Without PA By Nearly 50% Of Payers In Analysis

Dendreon’s Provenge (sipuleucel-T) and Sanofi-Aventis’ Jevtana (cabazitaxel) were covered by nearly 50% of commercial plans without prior authorization requirements during the first quarter of 2011, according to an analysis of payer policies for the novel prostate cancer therapies conducted by The Zitter Group.